Yoda Pharmaceuticals Company Description

Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders.

The company’s flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy.

It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury.

Yoda Pharmaceuticals Inc. was incorporated in 2019 and is based in Grand Cayman, the Cayman Islands.